HOXA9 and CD163 potentiate pancreatic ductal adenocarcinoma progression

• Päätekijät: Aiat Shaban Hemida (Tekijä), Mohamed Mohamady Ahmed (Tekijä), Mona Saeed Tantawy (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: BMC, 2024-10-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Abstract Background The role of HOXA9 requires investigations in pancreatic ductal adenocarcinoma (PDAC) as HOXA9 inhibitors are being developed. HOXA9 might attract CD163 expressed tumor associated macrophages (TAM) and could affect PDAC prognosis. This work aims to study the expression and relevan...